SCHEMBL2422282

SCHEMBL2422282

CC(C)(C)OC(=O)c1cc2ccccc2nc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
IKBKB O14920 1/20 0.43
GAA P10253 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
KDM4E B2RXH2 2/20 0.40
STAT3 P40763 1/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
ABCG2 Q9UNQ0 2/20 0.39
MAPT P10636 3/20 0.39
GLA P06280 2/20 0.38
THRB P10828 1/20 0.38
HIF1A Q16665 1/20 0.38
PPARA Q07869 2/20 0.37
ACHE P22303 1/20 0.37
ABCB1 P08183 1/20 0.37
GABRP O00591 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30081357 1.00 MEN1 (0.44) MEN1KMT2AIKBKBGAAALDH1A1
SCHEMBL16234345 0.83 KDM4E (0.51) MEN1KMT2AIKBKBALDH1A1HPGD
SCHEMBL7660079 0.81 MEN1 (0.42) MEN1KMT2AIKBKBGAAALDH1A1
SCHEMBL28230815 0.79 KMT2A (0.47) MEN1KMT2AIKBKBGAAALDH1A1
SCHEMBL23632474 0.79 MEN1 (0.44) MEN1KMT2AIKBKBGAAALDH1A1
SCHEMBL5861172 0.79 TSHR (0.54) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL2422281 0.79 ALDH1A1 (0.47) MEN1KMT2AGAAALDH1A1HPGD
SCHEMBL28231761 0.76 KMT2A (0.44) MEN1KMT2AGAAALDH1A1HPGD
SCHEMBL28231808 0.76 MEN1 (0.41) MEN1KMT2AGAAALDH1A1HPGD
SCHEMBL28055302 0.75 HTR3A (0.41) MEN1KMT2AIKBKBGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230125667-A1 NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS US GOV VETERANS AFFAIRS (US) 2023-04-27 US disclosed
EP-2046733-B1 PROCESS FOR THE PREPARATION OF EPSILON-ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES ITALIANA SINT SPA (IT) 2011-10-05 EP disclosed
US-8026372-B2 Process for the preparation of ε-alkoxycarbonyllysines and their analogues F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2011-09-27 US disclosed
US-20090312557-A1 PROCESS FOR THE PREPARATION OF EPSILON -ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2009-12-17 US disclosed
EP-2046733-A1 PROCESS FOR THE PREPARATION OF EPSILON-ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2009-04-15 EP disclosed
WO-2008014811-A1 PROCESS FOR THE PREPARATION OF ε-ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312557-A1 PROCESS FOR THE PREPARATION OF EPSILON -ALKOXYCARBONYLLYSINES AND THEIR ANALOGUES AADAT, ALKBH3, BCAT2 MEN1 4482/4885KMT2A 73/4885IKBKB 239/4885
US-20230125667-A1 NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS BRCA1, MTPN, MUSK MEN1 302/4885KMT2A 1067/4885IKBKB 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.